Nebula Research & Development LLC Buys 58,844 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Nebula Research & Development LLC increased its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 325.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 76,914 shares of the company's stock after purchasing an additional 58,844 shares during the quarter. Nebula Research & Development LLC owned approximately 0.09% of Syndax Pharmaceuticals worth $1,017,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. R Squared Ltd bought a new stake in shares of Syndax Pharmaceuticals in the fourth quarter valued at $26,000. Cape Investment Advisory Inc. raised its stake in Syndax Pharmaceuticals by 157.1% in the 4th quarter. Cape Investment Advisory Inc. now owns 6,427 shares of the company's stock valued at $85,000 after acquiring an additional 3,927 shares during the period. KBC Group NV lifted its holdings in Syndax Pharmaceuticals by 104.8% during the fourth quarter. KBC Group NV now owns 6,954 shares of the company's stock valued at $92,000 after purchasing an additional 3,559 shares during the last quarter. Optimize Financial Inc bought a new position in Syndax Pharmaceuticals during the fourth quarter worth about $152,000. Finally, Guggenheim Capital LLC purchased a new position in shares of Syndax Pharmaceuticals in the fourth quarter worth about $157,000.

Insider Activity at Syndax Pharmaceuticals

In related news, insider Neil Gallagher sold 4,618 shares of the business's stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $71,579.00. Following the completion of the sale, the insider now owns 85,095 shares in the company, valued at $1,318,972.50. The trade was a 5.15 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Michael A. Metzger sold 13,288 shares of the stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $205,964.00. Following the transaction, the chief executive officer now owns 300,121 shares in the company, valued at $4,651,875.50. The trade was a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 21,683 shares of company stock valued at $336,087 over the last 90 days. 4.10% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

SNDX has been the subject of several analyst reports. Scotiabank cut their price objective on shares of Syndax Pharmaceuticals from $18.00 to $16.00 and set a "sector perform" rating for the company in a report on Wednesday, January 8th. JPMorgan Chase & Co. raised their price target on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the stock an "overweight" rating in a report on Thursday, March 20th. HC Wainwright reiterated a "buy" rating and set a $51.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th. Citigroup cut their target price on Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating for the company in a research note on Tuesday, March 4th. Finally, StockNews.com raised Syndax Pharmaceuticals to a "sell" rating in a report on Thursday, April 10th. One analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $36.20.

Syndax Pharmaceuticals Trading Up 0.2 %

Shares of NASDAQ SNDX opened at $13.33 on Friday. The business has a 50-day moving average of $13.08 and a 200-day moving average of $14.87. The firm has a market capitalization of $1.15 billion, a price-to-earnings ratio of -3.67 and a beta of 1.28. Syndax Pharmaceuticals, Inc. has a 12 month low of $9.66 and a 12 month high of $25.07.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its quarterly earnings results on Monday, March 3rd. The company reported ($1.10) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.79). The business had revenue of $7.68 million for the quarter, compared to analyst estimates of $86.32 million. On average, analysts predict that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).

Want to see what other hedge funds are holding SNDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.